Updated Phase 2 Agent-797 Gastric Cancer Data at AACR IO
MiNK Therapeutics will present interim Phase 2 data on AgenT-797 combined with botensilimab and balstilimab for refractory gastric cancer...
Jon Napitupulu
Orchestra Biomed Announces Favorable AVIM Therapy Data for Heart Failure at THT 2025
Orchestra BioMed Holdings announced positive data from a retrospective analysis of its MODERATO II study, demonstrating that atrioventricular interval...
Windtree Therapeutics Presents Late-Breaking Istaroxime Data at Heart Failure Conference
Windtree Therapeutics announced a presentation on its drug istaroxime at the Technology and Heart Failure Therapeutics Conference. The presentation...
Escharex’s Pivotal Trial for Venous Leg Ulcers
MediWound has launched VALUE, a pivotal Phase III trial for EscharEx®, its enzymatic treatment for venous leg ulcers (VLUs)....
Aptose’s Triple Drug AML Therapy Shows Promise in Phase 1/2 Trial
Aptose Biosciences reported promising early results from its Phase 1/2 TUSCANY trial, testing a triplet therapy of tuspetinib, venetoclax,...
Ati-2138: Potent, Selective Inhibitor of ITK and JAK3
Aclaris Therapeutics announced the publication of research on ATI-2138, a novel dual inhibitor of ITK and JAK3, currently in...
Tasso’s Patient-Centric Dried Blood Spot Technology
Tasso, a leader in patient-centric blood collection, launched its next-generation dried blood spot (DBS) sample collection system. This system...
Kairos Pharma and Huntsman Cancer Institute for ENV105 Phase 2 Trial
Kairos Pharma (NYSE American: KAPA) is expanding its Phase 2 clinical trial for ENV105, a drug targeting castrate-resistant prostate...
Allostem™ Shows Positive One-Year Results for Type 2 Diabetes
Creative Medical Technology Holdings, Inc. (CELZ) announced positive one-year follow-up data from a pilot study of CELZ-201 (AlloStem™) in...
Positive INB-100 Phase 1 Leukemia Trial Results Reported by in8bio
IN8bio’s Phase 1 trial of INB-100, a gamma-delta T cell therapy for complex leukemias like AML, has shown promising...